BNB Plus Corp. (UDJ1)

Overview

BNB Plus Corp. is an innovative biotechnology enterprise specializing in the development and commercialization of cutting-edge technologies for the production and detection of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Established in 1983 and located in Stony Brook, NY, the company has positioned itself at the forefront of biotechnological advancements through three distinct segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services.

Products and Services

• Therapeutic DNA Production Services:

  This segment focuses on the enzymatic manufacturing of synthetic DNA, which is essential for developing nucleic acid-based therapeutics. Additionally, BNB Plus Corp. has developed a proprietary RNA polymerase (RNAP) specifically designed for producing mRNA therapeutics, further enhancing its capabilities in the biotechnology field.

• MDx Testing Services:

  In this segment, BNB Plus Corp. is dedicated to the development of clinical molecular diagnostic tests and genetic testing services. These services are vital for clinical laboratory settings, providing accurate and reliable tests to assist in disease identification and management.

• DNA Tagging and Security Products and Services:

  This division concentrates on the detection of DNA, applying advanced technologies within industrial supply chains and security services. These products are designed to enhance traceability and security measures across various sectors, providing peace of mind through robust DNA detection solutions.